Procera Networks(PKT) on the AMEX is my most current trade idea. The stock is clearly gaining momentum. I provided a Live Chart strong buy recommendation on the stock at $.80 just a few days ago, and the stock surged through $1 yesterday for the first time since October and looking like it wants to work a lot higher.
It’s a software company- they’re in the business of helping ISPs (internet service providers) save money by routing their traffic more efficiently based on importance.
Jackson Spears, analyst at Robbins Group and personal acquitance, has a strong speculative buy recommendation on the stock. He believes their losses on $12 million in revenues in CY ’08 will convert to EPS of $.05 on $28 million in revs in CY ’09. His short term price target is $2.
The stock clearly is entitled to honorable mention for its chart this past week. As you can see, just since I posted the buy recommendation on the stock at $.80 on the 20th, the stock has already provided a 25% return. Volume and price are surging simultaneously.
People, things are starting to happen fast and furious. These absurdly oversold stocks are coming off the canvas and gaining ground. Don’t sit on the sidelines and watch these stocks start to trade back up. Act quickly and decisively when you read something you like. We’re going to start making money on a more consistent basis again.
It’s long overdue as we are a year into this Bear Market, and if you’re like me, it’s worn you out a bit. Time to get back to our former winning ways.
Comments and questions are welcome.
Hi what do you know about NVLX testing with U of Minn on the swine flu? Wow their timing seems it couldnt be better.
Editor: I’m not familiar with anything they are doing along those lines. Would make for a nice story, and if it makes the stock go up, in my opportunity it would be a chance to sell some and lighten up.
Just to let you know about NVLX this came out today.
Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine FluLast update: 4/29/2009 10:43:00 AMCHERRY HILL, N.J., April 29, 2009 /PRNewswire-FirstCall via COMTEX/ — Nuvilex, Inc. (NVLX), an emerging healthcare consumer products company, today announced that it will advance the release of Citroxin to domestic and international health agencies including hospitals, clinics, and medical offices as well as other at risk institutions and companies, such as schools and airlines. Nuvilex has proof of Citroxin’s effectiveness in eliminating swine influenza virus (SIV; H1N1 subtype) and avian influenza virus (AIV; H9N9 subtype) on surface areas but has not yet submitted Citroxin for EPA approval as an antiviral agent. Citroxin samples will be provided at no cost and the Company will provide technical assistance. Citroxin is being released early as the current Swine Flu outbreak requires the best products be deployed to combat the growing epidemic. Independent laboratory testing of Citroxin showed a 100% kill rate for the “big six” bacterial health threats, including E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, Streptococcus, and Black Mold. Citroxin is an EPA registered germicidal composition (EPA registration number 82723-1) and is patented in the US and world wide (US 7,439,218 and WIPO 2007/038265 A3). Interested parties should contact A. Peter Morello III, Ph.D., Director of Research at Nuvilex via a specially set up email address: citroxin@nuvilex.com for product information and specifications as well as to request a sample. “Given the seriousness of the threat of the spread of swine flu, we believe it is our duty to push hard to make Citroxin available as soon as possible,” said Martin E. Schmieg, Chairman and CEO of Nuvilex, Inc. “Much of the innovation in science and technology for combating big problems comes from small companies such as Nuvilex. Moving our discoveries into the world takes resources – investment capital, which has all but disappeared from the market because of the current economic downturn. If Citroxin takes root as envisioned, demand will outpace our manufacturing capabilities and it will be necessary for us to seek a commercial partner to move the product quickly into the marketplace.” Citroxin is a eco-friendly surface cleaner. The Company’s viral testing to date has been led by Sagar M. Goyal, D.V.M., Ph.D. at the University of Minnesota. Dr. Goyal has investigated the use of Citroxin to treat viral subtypes of SIV (H1N1). In Dr. Goyal’s first experiment, his team evaluated the ability of Citroxin (dilutions of 1:10 and 1:100) to inhibit the replication of SIV H1N1 in vitro. Compared to the controls, high concentrations of Citroxin (1:10 dilution) were found to be virucidal for SIV growing in MDCK (Madin-Darby canine kidney) cells. The Company, in conjunction with international based academic researchers, has also treated H9N9 AIV with Citroxin. In the AIV H9N9 experiments, Citroxin also served as a better virucidal agent when it received a smaller viral challenge (1000, 100, and 10 tissue culture infectious dose50, or TCID50, of virus). “Although Citroxin is not yet proven to be immunogenic, experiments do suggest that Citroxin can serve as an effective cleaner or disinfectant for surfaces that may have come into contact with SIV, AIV, or other types of virus particles,” said Dr. Morello. “We are ready, willing and able to help the global public health community in combating the swine flu outbreak.” About Nuvilex, Inc. Nuvilex, formerly eFoodSafety.com, Inc. is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company’s focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets.
So what does the sale of “4,587,000 shares of the Company’s restricted common stock, which were sold at $0.40 per share, for a total of $1,835,000″ do for the stock price? Could these shares be sold now or soon?
Editor: They needed to do a small financing in order to be in position to perform on current orders. Undoubtedly, it has resulted in today’s down tick. Most likely, it will roll right back up. The shares will not be eligible to be free trading for six months.